Optimizing Successful Outcomes for Repurposing Existing Pharmaceutical Compounds

Abstract

The present invention provides a process and method for preventing and/or treating protein based diseases, including, but not limited to: Alzheimer's and other amyloid based disease groups. This method recognizes correlative similarities across genomics, phenotypic and pharmacologic analytics and data to identify a list of existing compounds as high probability targets to act as inhibitors and/or stimulants close to a disease of interest. Pertinent genetic or epigenetic variances, or protein expression anomalies, are used to assemble a list of existing compounds through the use of artificial intelligence, machine learning and algorithmic relationships. This invention applies current genomic, phenotypic and pharmacological data to leverage data previously obtained in pursuit of other disease treatments. Accordingly, the current invention collapses cycle time to discovery and dramatically reduces costs. Through this system of active compounds created from tenuous relationships exhibits an elevated probability of success. Using a selection of algorithms that coordinate relationships including, but not limited to: genomic, epigenomic, phenotypic, protein dysregulation, cultural, pharmacological, etc., data, the present invention collapses cycle time of development and dramatically reduces costs by accessing data on target rich groups of previously tested abstractly related compounds.

1 . An improved method for repurposing a known compound for use in treating a disease for which said compound was not clinically prescribed comprising:
 a. Initiating process by identifying a genomic variance;   b. Inputting said variance into a database system;   c. Outputting a list of medical correlates, showing a relation to said variance;   d. Inputting said list into a database system;   e. Applying an artificially intelligent algorithm in outputting a second list of correlates comprising at least one feature selected from the group consisting of: genomic variances, cultural associations, location of medical events, chemical modulations, homeopathic modulations, cultural knowledge, timing of correlation event and treatment outcome;   f. Optionally reapplying said artificially intelligent algorithm to expand or focus said second list;   g. Optionally applying a second artificially algorithm to said output product of e to expand or focus said second list;   h. Repeating f and/or g as desired—including 0 times, if desired, and outputting said result(s);   i. Obtaining one or more biomodels comprising a genomic variance or product of a genomic variance identified in a and/or h;   j. Applying a compound or composition identified in h to at least one said biomodel;   k. Associating said genomic variance of said biomodel of j with a disease or symptom and scheduling further testing of said compound or composition with said disease or symptom; and   l. Supporting marketing for pharmaceutical or supplemental use of at least one said compound or composition whose testing exhibited positive result.   
     
     
         2 . The improved method of  claim 1  wherein said location is selected from the group consisting of: a geographic location, an altitude a vehicle, an organ, a tissue, a part of the anatomy and a biopsied sample. 
     
     
         3 . The improved method of  claim 1  wherein said one or more biomodels comprises at least one transgenic mouse. 
     
     
         4 . The improved method of  claim 1  wherein said supporting comprises filing a patent application. 
     
     
         5 . A method of identifying a compound that modulates at least one of a group of diseases, said method comprising:
 a. selecting i) a symptom or disease or ii) genomic variance;   b. feeding i) or ii) into a search field of a structured database;   c. querying said at least one structured database for content of one or a plurality of records referencing i) or ii);   d 1 . for i) selecting at least one record referencing a first genomic variance:   d2. for ii) selecting at least one record referencing a first symptom or disease;   e. correlating results of d x  (where x=1 or 2) with at least one recorded feature of said at least one record;   f. querying at least one structured database for content of one or a plurality of records referencing said at least one recorded feature;   g. listing one or more compounds and/or compositions related to controlling or attempting to control at least one symptom noted as a recorded feature in said one or a plurality of records referencing said at least one recorded feature;   h. identifying in said listing, and delisting compounds and/or compositions, if any, known to have been applied to controlling said at least one symptom; and:   i. delivering to a physical, chemical and/or biomodel at least one said one or more compounds and/or compositions, said at least one said one or more compounds and/or compositions listed in g and remaining after h;   j. determining effect of said one or more compounds and/or compositions;   k. selecting one or more compounds and/or compositions determined to have desired effect; and   l. identifying at least one of one or more compounds and/or compositions selected in k as said new pharmaceutical composition; or:   j. selecting at least one alternate compound or composition, at least one of said compounds and/or compositions delisted in h;   k. optionally: noting one or more undesired outcome(s), if any, resulting from said at least one alternate compound or composition being applied to controlling said at least one symptom;   l. selecting at least a second compound or composition to counteract at least one of said one or more undesired outcome(s);   m. confirming desired activity of said at least one second compound or composition; and   n. identifying as said new pharmaceutical composition, a composition comprising at least one said alternate compound to be used in conjunction with at least one said second compound said one or more compounds and/or compositions.   
     
     
         6 . A method of identifying a compound that modulates at least one of a group of diseases, said method comprising:
 d. selecting i) a symptom or disease or ii) genomic variance;   e. feeding i) or ii) into a search field of a structured database;   f. querying said at least one structured database for content of one or a plurality of records referencing i) or ii);   d 1 . for i) selecting at least one record referencing a genomic variance:   d 2 . for ii) selecting at least one record referencing a symptom or disease;   m. correlating results of d x  (where x=1 or 2) with at least one recorded feature of said at least one record;   n. querying at least one structured database for content of one or a plurality of records referencing said at least one recorded feature;   o. listing one or more compounds and/or compositions related to controlling or attempting to control at least one symptom noted as a recorded feature in said one or a plurality of records referencing said at least one recorded feature;   p. identifying in said listing, and delisting compounds and/or compositions, if any, known to have been applied to controlling said at least one symptom; and:   q. delivering to a physical, chemical and/or biomodel at least one said one or more compounds and/or compositions, said at least one said one or more compounds and/or compositions listed in g and remaining after h;   r. determining effect of said one or more compounds and/or compositions;   s. selecting one or more compounds and/or compositions determined to have desired effect; and   t. identifying at least one of one or more compounds and/or compositions selected in k as said new pharmaceutical composition; or:   o. selecting at least one alternate compound or composition, at least one of said compounds and/or compositions delisted in h;   p. optionally: noting one or more undesired outcome(s), if any, resulting from said at least one alternate compound or composition being applied to controlling said at least one symptom;   q. selecting at least a second compound or composition to counteract at least one of said one or more undesired outcome(s);   r. confirming desired activity of said at least one second compound or composition; and   s. identifying as said new pharmaceutical composition, a composition comprising at least one said alternate compound to be used in conjunction with at least one said second compound said one or more compounds and/or compositions.   
     
     
         7 . A method for identifying a new pharmaceutical composition for treating a disease, said method comprising:
 a. selecting a first symptom or a first genomic variance;   b. optionally: querying a database for a correlative relationship between said first symptom and a correlate genomic variance or between said first genomic variance and a correlate symptom;   c. querying at least one database with at least one selection of a and/or at least one correlate of b to provide an identification of a first disease;   d. accessing at least one structured database;   e. querying said at least one structured database for content of one or a plurality of records referencing said first disease;   f. selecting at least one record referencing said first disease;   g. correlating said first disease with at least one recorded feature of said at least one record;   h. querying at least one structured database for content of one or a plurality of records referencing said at least one recorded feature;   i. listing one or more compounds and/or compositions related to controlling or attempting to control at least one symptom noted as a recorded feature in said one or a plurality of records referencing said at least one recorded feature;   j. identifying in said listing, and delisting compounds and/or compositions, if any, known to have been applied to controlling said at least one disease; and:   k. delivering to a physical, chemical and/or biomodel at least one said one or more compounds and/or compositions, said at least one said one or more compounds and/or compositions listed in i and remaining after j;   l. determining effect of said one or more compounds and/or compositions;   m. selecting one or more compounds and/or compositions determined to have desired effect; and   n. identifying at least one of one or more compounds and/or compositions selected in I as said new pharmaceutical composition; or:   k. selecting at least one alternate compound or composition, at least one of said compounds and/or compositions delisted in j;   l. optionally: noting one or more undesired outcome(s), if any, resulting from said at least one alternate compound or composition being applied to controlling said at least one symptom;   m. selecting at least a second compound or composition, said at least one second compound or composition selected to contribute modulation of said one or more undesired outcome(s);   n. confirming desired activity of said at least one second compound or composition; and   o. identifying as said new pharmaceutical composition, a composition comprising at least one said alternate compound to be used in conjunction with at least one said second compound said one or more compounds and/or compositions.   
     
     
         8 . The method of  claim 5  further comprising:
 m. or o. delivering said new pharmaceutical composition to at least one individual. 
 
     
     
         9 . The method of  claim 6  further comprising:
 o. or p. delivering said new pharmaceutical composition to at least one individual. 
 
     
     
         10 . The method of  claim 8  wherein said delivering comprises providing an individual with a substance selected from the group consisting of: pill, tablet, osmotic pump, ointment, inhalant, eye drop, sublingual substance, mouthwash, pastille, gel, hydrogel, injection, subdermal implant, powder, emulsion, elixir, gum, cream, paste, liniment, liposome, skin patch, suppository, IUD, microsphere, nanosphere and nasal spray. 
     
     
         11 . The method of  claim 9  wherein said delivering comprises providing an individual with a substance selected from the group consisting of: pill, tablet, osmotic pump, ointment, inhalant, eye drop, sublingual substance, mouthwash, pastille, gel, hydrogel, injection, subdermal implant, powder, emulsion, elixir, gum, cream, paste, liniment, liposome, skin patch, suppository, IUD, microsphere, nanosphere and nasal spray. 
     
     
         12 . The method of  claim 5  wherein at least one of said at least one undesired outcome(s) is selected from the group consisting of: countering said one or more undesired outcome(s) (optionally, if any), anti-oxidation, anti-inflammation, diuresis, anti-diureses, anti-depression, hypertension, hypotension, naturesis, anti-naturesis, kalesis, anti-kalesis, mitochondrial fission, mitochondrial fusion, mitochondrial motility, ROS damage, 0 2  consumption and interferon production 
     
     
         13 . The method of  claim 6  wherein at least one of said at least one undesired outcome(s) is selected from the group consisting of: countering said one or more undesired outcome(s) (optionally, if any), anti-oxidation, anti-inflammation, diuresis, anti-diureses, anti-depression, hypertension, hypotension, naturesis, anti-naturesis, kalesis, anti-kalesis, mitochondrial fission, mitochondrial fusion, mitochondrial motility, ROS damage, 0 2  consumption and interferon production 
     
     
         14 . A method for producing a new pharmaceutical composition, said method comprising:
 a. selecting a first symptom of a first disease;   b. providing an identification of said first disease;   c. accessing at least one structured database;   d. querying said at least one structured database for content of one or a plurality of records selected from the group consisting of: record(s) referencing said first symptom and record(s) referencing said first disease;   e. selecting at least one first record obtained from d;   f. selecting at least one chemical compound relating to said at least one first record;   g. querying at least one structured database for content of one or a plurality of records referencing said at least one chemical compound to obtain a listing comprising diseases and symptoms relating to said compound;   h. querying at least one structured database with results of said listing obtained from the query in g to obtain a compilation of compounds associated with symptoms or diseases of said listing;   i. analyzing compounds related in f. and h. for similarities and distinctions;   j. querying at least one structured database for negative assessments of compounds related in f. and h.;   k. correlating negative assessments with similarities and distinctions of i.;   l. associating chemical structure with said similarities and distinctions;   m. selecting chemical structural features minimizing said negative assessments;   n. designing a chimeric compound or a library of chimeric compounds maintaining at least one feature of at least one compound related in f. and h. while discarding one or more chemical feature selected in m.; and   o. producing at least one compound designed in n.   
     
     
         15 . The method of  claim 14  further comprising:
 e1. querying at least one structured database for a compound previously applied to modulate at least one characteristic associated with said first symptom or said first disease to obtain a compound identifying record; and 
 in f. selecting a chemical compound relating to said compound identifying record. 
 
     
     
         16 . The method of  claim 5  further comprising correlating said symptom or disease with at least one genomic variant, constructing a knock-out biomodel of said genomic variant for testing said new pharmaceutical composition. 
     
     
         17 . The method of  claim 6  further comprising correlating said symptom or disease with at least one genomic variant, constructing a knock-out biomodel of said genomic variant for testing said compound designed in n. 
     
     
         18 . The method of  claim 5  further comprising correlating said symptom or disease with at least one genomic variant, constructing a knock-out biomodel of said genomic variant for testing said new pharmaceutical compound or composition. 
     
     
         19 . A pharmaceutical composition identified in accordance with  claim 5 . 
     
     
         20 . The composition of  claim 19  comprising at least one component selected from the group consisting of: an antiemetic, an alpha and/or beta adrenergic active compound, an analgesic, a muscle relaxant, a metabolic stimulant, caffeine, an antioxidant and an anti-inflammatory compound. 
     
     
         21 . A pharmaceutical composition identified in accordance with  claim 6 . 
     
     
         22 . The composition of  claim 21  comprising at least one component selected from the group consisting of: an antiemetic, an alpha and/or beta adrenergic active compound, an analgesic, a muscle relaxant, a metabolic stimulant, caffeine, an antioxidant and an anti-inflammatory compound. 
     
     
         23 . A pharmaceutical composition comprising a compound produced in accordance with  claim 18 . 
     
     
         24 . The composition of  claim 23  comprising at least one component selected from the group consisting of: an antiemetic, an alpha and/or beta adrenergic active compound, an analgesic, a muscle relaxant, a metabolic stimulant, caffeine, an antioxidant and an anti-inflammatory compound. 
     
     
         25 . The pharmaceutical composition of  claim 22  in a delivery format selected from the group consisting of: pill, tablet, osmotic pump, ointment, inhalant, eye drop, sublingual substance, mouthwash, pastille, gel, hydrogel, injection, subdermal implant, powder, emulsion, elixir, gum, cream, paste, liniment, liposome, skin patch, suppository, IUD, microsphere, nanosphere and nasal spray. 
     
     
         26 . The composition of  claim 23  comprising at least one compound selected from the group consisting of: cannabigerolic acid (CBGA); cannabigerolic acid monomethylether (CBGAM); cannabigerol (CBG); cannabigerol monomethylether (CBGM); cannabigerovarinic acid (CBGVA); cannabigerovarin (CBGV), cannabichromenic acid (CBCA); cannabichromene (CBC); cannabichromevarinic acid (CBCVA); cannabichromevarin (CBCV); cannabidiolic acid (CBDA); cannabidiol (CBD); cannabidiol monomethylether (CBDM); cannabidiol C 4  (CBD-C4); cannabidivarinic acid (CBDVA); cannabidivarin (CBDV); cannabidiorcol (CBD-C1); Δ 9 -tetrahydrocannabinolic acid A (THCA-A); Δ 9 -tetrahydrocannabinolic acid B (THCA-B); 6a,10a-trans-6a,7,8,10a-tetrahydro-6,6,9- trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol, (Δ 9 -tetrahydrocannabinol, THC); Δ 9 -tetrahydrocannabinolic acid-C4 (THCA-C4); Δ 9 -tetrahydrocannabinol-C4 (THC-C4); Δ 9 -tetrahydrocannabivarinic acid (THCVA); Δ 9 -tetrahydrocannabivarinic (THCV); Δ 7 -cis-isotetrahydrocannabivarin; Δ 9 -tetrahydrocannabiorcolic acid (THCA-C1); tetrahydrocannabiorcol (THC-C1), Δ 8 -tetrahydrocannabinolic acid (Δ 8 -TCA); Δ 8 -tetrahydrocannabinol (Δ 8 -THC), cannabicyclol (CBL); cannabicyclolicacid (CBLA); cannabicyclovarin (CBLV), cannabiesoic acid A (CBEA-A); cannabiesoic acid B (CBEA-B); cannabieson (CBE), cannabinolic acid (CBNA); cannabinol (CBN); cannabinol methylether (CBNM); cannabinol-C4 (CBN-C4); cannabivarin (CBV); cannabinol-C2 (CBN-C2); cannabiorcol (CBN-C1); cannabinodiol (CBND); cannabinidivarin (CBDV); cannabitriol (CBT); 10-ethoxy-9-hydroxy-Δ-6a-tetrahydrocannabinol (10-EHDT); 8,9-dihydroxy-Δ-6a-tetrahydrocannabinol (8,9-DHDT); cannabitriolvarin (CBTV); ethoxy-cannabitriolvarin (CBTVE), dehydrocannabifuran (DCBF); cannabifuran (CBF); cannabichromanon (CBCN); cannabicitran (CBT); 10-oxo-Δ-6a-tetrahydrocannabinol (OTHC); Δ 9 -cis-tetrahydrocannabinol (cis-THC); 3,4,5,6-tetrahydro-7-hydroxy-α-α-2-trimethyl-9-n-propyl-2,6-methano-2H-1-benzoxocin-5-methanol (2H-iso-HHCV); cannabiripsol (CBR); trihydroxy-Δ 9 -tetrahydrocannabinol (triOH-THC); at least one phytoantiinflammatory compound; N-acetylcysteine; at least one carotenoid selected from the group consisting of: β-carotene, lycopene, lutein, astaxanthin and zeaxanthin; L-cysteine; N-acetylcysteine and analogues and metabolic precursors thereof; glutathione (GSH); coenzyme Q10 (CoQ10); α-lipoic acid; resveratrol; a flavonoid; milk thistle; gingko; biloba; gotu-kola; at least one bioflavonoid selected from the group consisting of: 1,2 dithiolane-3-pentanoic acid; lipoate (α-LΔ − ), and dihydrolipoate (DLA − ); vitamin E, vitamin C, riboflavin (B 2 ); L-creatine; L-arginine; L-carnitine; cyclosporin A; manganese; magnesium; zinc; carnosine; folinic acid; dichloroacetate and succinate. 
     
     
         27 . The composition of  claim 25  wherein said at least one phytoantiinflammatory compound is selected from the group consisting of: curcumin, colchicine, resveratrol, capsaicin, epigallocatechin-3-gallate and quercetin. 
     
     
         28 . The composition of  claim 21  comprising at least one compound selected from the group consisting of: cannabigerolic acid (CBGA); cannabigerolic acid monomethylether (CBGAM); cannabigerol (CBG); cannabigerol monomethylether (CBGM); cannabigerovarinic acid (CBGVA); cannabigerovarin (CBGV), cannabichromenic acid (CBCA); cannabichromene (CBC); cannabichromevarinic acid (CBCVA); cannabichromevarin (CBCV); cannabidiolic acid (CBDA); cannabidiol (CBD); cannabidiol monomethylether (CBDM); cannabidiol C 4  (CBD-C4); cannabidivarinic acid (CBDVA); cannabidivarin (CBDV); cannabidiorcol (CBD-C1); Δ 9 -tetrahydrocannabinolic acid A (THCA-A); Δ 9 -tetrahydrocannabinolic acid B (THCA-B); 6a,10a-trans-6a,7,8,10a-tetrahydro-6,6,9- trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol, (Δ 9 -tetrahydrocannabinol, THC); Δ 9 -tetrahydrocannabinolic acid-C4 (THCA-C4); Δ 9 -tetrahydrocannabinol-C4 (THC-C4); Δ 9 -tetrahydrocannabivarinic acid (THCVA); Δ 9 -tetrahydrocannabivarinic (THCV); Δ 7 -cis-isotetrahydrocannabivarin; Δ 9 -tetrahydrocannabiorcolic acid (THCA-C1); tetrahydrocannabiorcol (THC-C1), Δ 8 -tetrahydrocannabinolic acid (Δ 8 -TCA); Δ 8 -tetrahydrocannabinol (Δ 8 -THC), cannabicyclol (CBL); cannabicyclolicacid (CBLA); cannabicyclovarin (CBLV), cannabiesoic acid A (CBEA-A); cannabiesoic acid B (CBEA-B); cannabieson (CBE), cannabinolic acid (CBNA); cannabinol (CBN); cannabinol methylether (CBNM); cannabinol-C4 (CBN-C4); cannabivarin (CBV); cannabinol-C2 (CBN-C2); cannabiorcol (CBN-C1); cannabinodiol (CBND); cannabinidivarin (CBDV); cannabitriol (CBT); 10-ethoxy-9-hydroxy-Δ-6a-tetrahydrocannabinol (10-EHDT); 8,9-dihydroxy-Δ-6a-tetrahydrocannabinol (8,9-DHDT); cannabitriolvarin (CBTV); ethoxy-cannabitriolvarin (CBTVE), dehydrocannabifuran (DCBF); cannabifuran (CBF); cannabichromanon (CBCN); cannabicitran (CBT); 10-oxo-Δ-6a-tetrahydrocannabinol (OTHC); Δ 9 -cis-tetrahydrocannabinol (cis-THC); 3,4,5,6-tetrahydro-7-hydroxy-α-α-2-trimethyl-9-n-propyl-2,6-methano-2H-1-benzoxocin-5-methanol (2H-iso-HHCV); cannabiripsol (CBR); trihydroxy-Δ 9 -tetrahydrocannabinol (triOH-THC); at least one phytoantiinflammatory compound; N-acetylcysteine; at least one carotenoid selected from the group consisting of: β-carotene, lycopene, lutein, astaxanthin and zeaxanthin; L-cysteine; N-acetylcysteine and analogues and metabolic precursors thereof; glutathione (GSH); coenzyme Q10 (CoQ10); α-lipoic acid; resveratrol; a flavonoid; milk thistle; gingko; biloba; gotu-kola; at least one bioflavonoid selected from the group consisting of: 1,2 dithiolane-3-pentanoic acid; lipoate (α-LA − ), and dihydrolipoate (DLA − ); vitamin E, vitamin C, riboflavin (B 2 ); L-creatine; L-arginine; L-carnitine; cyclosporin A; manganese; magnesium; zinc; carnosine; folinic acid; dichloroacetate and succinate. 
     
     
         29 . The composition of  claim 28  wherein said at least one phytoantiinflammatory compound is selected from the group consisting of: curcumin, colchicine, resveratrol, capsaicin, epigallocatechin-3-gallate and quercetin. 
     
     
         30 . The composition of  claim 23  comprising at least one compound selected from the group consisting of: cannabigerolic acid (CBGA); cannabigerolic acid monomethylether (CBGAM); cannabigerol (CBG); cannabigerol monomethylether (CBGM); cannabigerovarinic acid (CBGVA); cannabigerovarin (CBGV), cannabichromenic acid (CBCA); cannabichromene (CBC); cannabichromevarinic acid (CBCVA); cannabichromevarin (CBCV); cannabidiolic acid (CBDA); cannabidiol (CBD); cannabidiol monomethylether (CBDM); cannabidiol C 4  (CBD-C4); cannabidivarinic acid (CBDVA); cannabidivarin (CBDV); cannabidiorcol (CBD-C1); Δ 9 -tetrahydrocannabinolic acid A (THCA-A); Δ 9 -tetrahydrocannabinolic acid B (THCA-B); 6a,10a-trans-6a,7,8,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol, (Δ 9 -tetrahydrocannabinol, THC); Δ 9 -tetrahydrocannabinolic acid-C4 (THCA-C4); Δ 9 -tetrahydrocannabinol-C4 (THC-C4); Δ 9 -tetrahydrocannabivarinic acid (THCVA); A 9 -tetrahydrocannabivarinic (THCV); A′-cis-isotetrahydrocannabivarin; Δ 9 -tetrahydrocannabiorcolic acid (THCA-C1); tetrahydrocannabiorcol (THC-C1), Δ 8 -tetrahydrocannabinolic acid (Δ 8 -TCA); Δ 8 -tetrahydrocannabinol (Δ 8 -THC), cannabicyclol (CBL); cannabicyclolicacid (CBLA); cannabicyclovarin (CBLV), cannabiesoic acid A (CBEA-A); cannabiesoic acid B (CBEA-B); cannabieson (CBE), cannabinolic acid (CBNA); cannabinol (CBN); cannabinol methylether (CBNM); cannabinol-C4 (CBN-C4); cannabivarin (CBV); cannabinol-C2 (CBN-C2); cannabiorcol (CBN-C1); cannabinodiol (CBND); cannabinidivarin (CBDV); cannabitriol (CBT); 10-ethoxy-9-hydroxy-Δ-6a-tetrahydrocannabinol (10-EHDT); 8,9-dihydroxy-Δ-6a-tetrahydrocannabinol (8,9-DHDT); cannabitriolvarin (CBTV); ethoxy-cannabitriolvarin (CBTVE), dehydrocannabifuran (DCBF); cannabifuran (CBF); cannabichromanon (CBCN); cannabicitran (CBT); 10-oxo-Δ-6a-tetrahydrocannabinol (OTHC); Δ 9 -cis-tetrahydrocannabinol (cis-THC); 3,4,5,6-tetrahydro-7-hydroxy-α-α-2-trimethyl-9-n-propyl-2,6-methano-2H-1-benzoxocin-5-methanol (2H-iso-HHCV); cannabiripsol (CBR); trihydroxy-Δ 9 -tetrahydrocannabinol (triOH-THC); at least one phytoantiinflammatory compound; N-acetylcysteine; at least one carotenoid selected from the group consisting of: β-carotene, lycopene, lutein, astaxanthin and zeaxanthin; L-cysteine; N-acetylcysteine and analogues and metabolic precursors thereof; glutathione (GSH); coenzyme Q10 (CoQ10); α-lipoic acid; resveratrol; a flavonoid; milk thistle; gingko; biloba; gotu-kola; at least one bioflavonoid selected from the group consisting of: 1,2 dithiolane-3-pentanoic acid; lipoate (α-LA − ), and dihydrolipoate (DLA − ); vitamin E, vitamin C, riboflavin (B 2 ); L-creatine; L-arginine; L-carnitine; cyclosporin A; manganese; magnesium; zinc; carnosine; folinic acid; dichloroacetate and succinate. 
     
     
         31 . The composition of  claim 30  wherein said at least one phytoantiinflammatory compound is selected from the group consisting of: curcumin, colchicine, resveratrol, capsaicin, epigallocatechin-3-gallate and quercetin. 
     
     
         32 . The method of  claim 5  wherein said new pharmaceutical composition is applied to treating a second symptom or second disease wherein said symptom is not identical to said second symptom or said disease is not identical to said second disease. 
     
     
         33 . The method of  claim 6  wherein said new pharmaceutical composition is applied to treating a second disease wherein said first disease is not identical to said second disease. 
     
     
         34 . The method of  claim 18  wherein said new pharmaceutical composition is applied to treating a second symptom or second disease wherein said first symptom is not identical to said second symptom or said first disease is not identical to said second disease.